TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the first quarter of fiscal year 2024.
'Although revenue and profit decreased year on year due to the temporary impact of Ronapreve in the first quarter of 2024, the core business started off strong. In Japan, the sales of new products Phesgo and Vabysmo and a mainstay product Enspryng grew, but was notably impacted by the COVID-19 treatment Ronapreve, which its supply to the government has completed in the first quarter last year. As a result, domestic sales decreased by 46.4%. Overseas sales increased, with the substantial increase in exports of Hemlibra to Roche, despite the decrease in Actemra exports. In research and development, Piasky, our fifth global product, was approved in China and Japan.
Currently, reviews for approval of the medicine are underway in other areas including the United States, Europe, and Taiwan. We aim to contribute to the treatment of paroxysmal nocturnal hemoglobinuria by providing a new option that improves convenience for patients affected by the disease, around the world. In addition, Alecensa was approved by the U.S. FDA for adjuvant treatment of ALK-positive non-small cell lung cancer. There are no other ALK inhibitors approved for this indication, bringing a new approach to patients. Regarding nemolizumab, another in-house project, development conducted by our out-licensing partners in Japan and overseas is making steady progress. In Japan, Mitchga as its product name was approved for the treatment of pruritus associated with atopic dermatitis in children aged 6 to 12 years, and for prurigo nodularis. Outside of Japan, the application was accepted by the U.S. and European authorities for the treatment of atopic dermatitis and prurigo nodularis. We will continue to drive forward the development of innovative medicines to provide new value to patients,' said Dr. Osamu Okuda, Chugai's President and CEO.
First quarter results for 2024
Chugai reported decreased revenue and operating profit year on year for the first quarter (Core-basis).
Regarding revenue, domestic sales decreased by 46.4% year on year. In the oncology field, although mature products such as Avastin were impacted by the NHI drug price revision and biosimilars, the overall decrease remained at 6.5% contributed by growth of new product Phesgo. In the specialty field, sales decreased by approximately 65%, mainly due to the completion of supply of Ronapreve to the government, which recorded JPY81.2 billion in the first quarter of last year, while our our new product Vabysmo grew and our mainstay product Enspryng performed well. Overseas sales increased year on year. Exports of Hemlibra increased by approximately 25%, exceeding the decrease in exports of Actemra. Other revenue increased substantially by approximately 60%, mainly driven by the increase in one-time income.
Cost to sales ratio improved by 16.3 percentage points year-on-year to 35.5%, mainly due to a change in the product mix. Research and development expenses increased mainly due to investments into drug discovery and early development, and increases associated with the progress of development projects. Selling, general and administration expenses remained at the same level as the previous year. Other operating income (expense) was JPY0.2 billion in income. As a result, Core operating profit totaled JPY102.1 billion (-3.1%).
R&D activities
Chugai also made good progress in research and development, in both early and late stages of developments, particularly in maximizing the value of in-house developed products and mainstay products. Regarding approvals, our fifth global product Piasky, a humanized anti-complement (C5) monoclonal antibody discovered by Chugai, has been approved for the first time in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), followed by approval in Japan. It is under review for PNH by other regulatory authorities, including in the United States, Europe, and Taiwan. Piasky is the second approved drug applying Chugai's Recycling Antibody technology, following Enspryng. Another Chugai originated medicine, anti-IL-31RA, a humanized monoclonal antibody Mitchga (generic name: nemolizumab), has also been approved in Japan for additional indications including treatment for pruritus associated with atopic dermatitis (children aged 6 and
CHUGAI PHARMACEUTICAL CO., LTD 
